Efficacy of Ramelteon on Transient Insomnia in Healthy Adults

Sponsor

Takeda (Industry)

Overall Status

Completed

CT.gov ID

NCT00671398

Collaborator

(none)

289

Enrollment

Locations

Arms

Duration (Months)

24.1

Patients Per Site

4.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of Ramelteon, once daily (QD), in healthy subjects within a sleep lab.

Condition or Disease	Intervention/Treatment	Phase
Transient Insomnia	Drug: Ramelteon Drug: Ramelteon Drug: Placebo	Phase 3

Detailed Description

Insomnia is characterized by difficulties initiating and maintaining sleep, or of non-restorative and non-refreshing sleep. Transient insomnia affects approximately one-third to one-half of the US population, based on the results of 2 surveys of representative samples of the adult US population conducted by the Gallup Organization in which respondents were asked if they had "ever had difficulty sleeping." Based on reports of "regular" or "frequent" sleep difficulty, results from the same studies suggest that approximately one-tenth of the US population experiences chronic insomnia. The ideal treatment for insomnia would reduce the latency to onset of sleep and increase total sleep time, without a negative impact on sleep architecture and without safety concerns or next-day effects.

Ramelteon is a selective melatonin-1 receptor agonist under global development by Takeda Chemical Industries, Ltd., for the treatment of transient and chronic insomnia and for the treatment of Circadian Rhythm Sleep Disorders.

This study is being conducted to evaluate the safety and efficacy of a single dose of Ramelteon in normal healthy subjects in a sleep lab model of transient insomnia. Participation is this study is anticipated to be about 3 weeks.

Study Design

Study Type:

Interventional

Actual Enrollment :

289 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model of Transient Insomnia

Study Start Date :

Dec 1, 2002

Actual Primary Completion Date :

May 1, 2003

Actual Study Completion Date :

May 1, 2003

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Ramelteon 8 mg QD	Drug: Ramelteon Ramelteon 8 mg, tablets, orally for one night only. Other Names: Rozerem™ TAK-375
Experimental: Ramelteon 16 mg QD	Drug: Ramelteon Ramelteon 16 mg, tablets, orally for one night only Other Names: Rozerem™ TAK-375
Placebo Comparator: Placebo	Drug: Placebo Ramelteon placebo-matching tablets, orally for one night only

Arm

Intervention/Treatment

Experimental: Ramelteon 8 mg QD

Drug: Ramelteon

Ramelteon 8 mg, tablets, orally for one night only.

Other Names:

Rozerem™

TAK-375

Experimental: Ramelteon 16 mg QD

Drug: Ramelteon

Ramelteon 16 mg, tablets, orally for one night only

Other Names:

Rozerem™

TAK-375

Placebo Comparator: Placebo

Drug: Placebo

Ramelteon placebo-matching tablets, orally for one night only

Outcome Measures

Primary Outcome Measures

Latency to Persistent Sleep from 1 night of polysomnography (PSG) recording in a sleep laboratory. [Day 1]

Secondary Outcome Measures

Total Sleep Time. [Days 1 and 2.]
Sleep Efficiency. [Days 1 and 2.]
Wake Time after Persistent Sleep Onset. [Days 1 and 2.]
Number of Awakenings after Persistent Sleep. [Days 1 and 2.]
Subjective Sleep Latency. [Day 2]
Subjective Total Sleep Time. [Day 2]
Subjective Sleep Quality. [Day 2]
Subjective Wake Time after Sleep Onset. [Day 2]
Subjective Number of Awakenings. [Day 2]
Subjective Ease of Falling Back to Sleep after Awakening. [Day 2]
Stage 1 Nonrapid Eye Movement (NREM) Sleep [Day 2.]
Stage 2 Nonrapid Eye Movement (NREM) Sleep [Day 2.]
Stage 3/4 Nonrapid Eye Movement (NREM) Sleep [Day 2.]
Latency to Rapid Eye Movement (REM) Sleep [Day 2.]
Percentage of Total Sleep Time in REM Sleep [Day 2.]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 64 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria

Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
Habitual bedtime is between 8:30 p.m. and 12:00 a.m.
Sleeps 6.5 to 8 hours per night and has a subjective sleep latency of less than or equal to 30 minutes.
Body mass index between 18 and 34, inclusive.

Exclusion Criteria:

Any history of insomnia.
Spent one or more nights in a sleep laboratory.
Epworth Sleepiness Scale score of greater than 10.
Known hypersensitivity to Ramelteon or related compounds, including melatonin.
Previously participated in a study involving Ramelteon.
Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to Day 1, whichever is longer.
Sleep schedule changes required by employment (ie, shift work) within three months preceding Day 1 or has flown across greater than three time zones within seven days prior to screening.
Participated in a weight loss program or substantially altered their exercise routine within 30 days prior to Day 1.
History of seizures, sleep apnea, chronic obstructive pulmonary disease, restless leg syndrome, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
History of a psychiatric disorder (including anxiety or depression) within the past 12 months.
History of drug addiction or drug abuse within the past 12 months.
Any physical or psychiatric disorder that may be associated with sleep disturbance.
History of alcohol abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised and/or regularly consumes 4 or more alcoholic drinks per day.
Current significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic or metabolic disease.
Uses tobacco products during nightly awakenings.
Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
Positive hepatitis panel.
Positive urine drug screen including alcohol at screening or a positive breathalyzer test at check-in.
Any additional condition(s) that in the investigator's opinion would
affect sleep-wake function
prohibit the subject from completing the study
not be in the best interest of the subject.
Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:
Anxiolytics
Hypnotics
Antidepressants
Anticonvulsants
Sedating H1 antihistamines
Systemic steroids
Respiratory stimulants (eg, theophylline)
Decongestants
Over-the-counter and prescription stimulants
Over-the-counter and prescription diet aids
Central nervous system active drugs
Narcotic analgesics
All beta blockers
St. John's Wort
Kava-kava
gingko biloba

Contacts and Locations

Locations

	City	State	Country
1	Palm Springs	California	United States
2	San Diego	California	United States
3	Miami	Florida	United States
4	Pembroke Pines	Florida	United States
5	Atlanta	Georgia	United States
6	Overland Park	Kansas	United States
7	New York	New York	United States
8	Rochester	New York	United States
9	Cincinnati	Ohio	United States
10	Dublin	Ohio	United States
11	Columbia	South Carolina	United States
12	Houston	Texas	United States